iFabric's scrubs trial results published in journal

Executive Summary

• iFabric Corp. announced the publication of clinical trial results in the Journal of Hospital Infection demonstrating that its Protx2 and ecoPEL treated scrubs significantly reduce bacterial loads in real-world healthcare settings.
• The study, conducted by subsidiary Intelligent Fabric Technologies (North America) Inc. at MemorialCare Saddleback Medical Center, marks the first successful anti-microbial textile trial to show statistically significant reductions in surface bacterial contamination compared to untreated scrubs.
• Management highlights the potential for Protx2 to become a cornerstone solution in infection prevention, offering market opportunities through reduced hospital-acquired infections, decreased readmissions, and lower healthcare costs.

Key Details

• Publication: Results published in the Journal of Hospital Infection, the editorially independent scientific publication of the Healthcare Infection Society.
• Study Conducted By: Intelligent Fabric Technologies (North America) Inc. (IFTNA), a subsidiary of iFabric Corp.
• Study Location: MemorialCare Saddleback Medical Center in Southern California.
• Study Leadership: Led by Cheryl Westlake, PhD, RN, ACNS-BC, FHFSA, FAHA, FAAN; Kathleen M. Young, MSN, RN, NPD-BC; Brandi Cassingham, MSN, RN; and Lisa Forsythe, MSN-Ed, RN, NPD-BC.
• Key Finding: Statistically significant reductions in bacterial loads on scrubs worn in a real-world health care setting.
• Technology Tested: Protx2 (anti-microbial) and ecoPEL (fluorine-free durable water repellent technology).
• Comparison: Treated scrubs showed significant and quantifiable reductions in surface bacterial contamination compared to untreated scrubs.
• Regulatory Status: Protx2 is currently registered with the U.S. Environmental Protection Agency and is freely available for use throughout the United States.
• Potential Benefits Identified:
  • Reduced infection rates by minimizing pathogen transfer.
  • Decreased patient readmissions.
  • Lower hospital costs via reduced treatment costs and staffing disruptions.
  • Protection beyond the hospital by reducing bacterial spread into homes and communities.

Notable Quotes

• Giancarlo Beevis, President and CEO of IFTNA: "Previous attempts using other anti-microbial chemistries have failed to produce results of this magnitude. This trial conclusively showed that scrubs treated with Protx2 and Protx2 combined with our ecoPEL fluorine-free durable water repellent technology achieved significant and quantifiable reductions in surface bacterial contamination compared to untreated scrubs -- proof that these proprietary technologies can deliver infection control performance unmatched in the industry."
• Giancarlo Beevis: "This is an extraordinary moment for IFTNA. For decades, infection prevention experts have looked for textile-based solutions that could truly reduce bacterial contamination in real-world hospital environments. Until now, no trial has achieved this level of measurable infection control benefits."
• Giancarlo Beevis: "I believe that this publication has the potential to draw the attention of some of the most respected leaders in infection prevention across the USA and globally, and positions Protx2 as a cornerstone solution in the fight against health-care-associated infections, providing a significant market opportunity for IFTNA."